Loading company…
Pangea Biomed uses computational transcriptomics to support cancer treatment selection and drug development.
Founded in 2018 and based in Tel Aviv, Israel, Pangea Biomed applies computational transcriptomics to oncology. Its ENLIGHT platform combines machine learning and RNA sequencing to match patients with therapies and develop precision drug products. In April 2022, it raised USD 7 million in seed funding led by NFX.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in